Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Up 20.5% in March

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 424,500 shares, a growth of 20.5% from the March 15th total of 352,300 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 137,600 shares, the days-to-cover ratio is currently 3.1 days.

Analyst Ratings Changes

Separately, Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $0.72 on Tuesday. The company has a market capitalization of $90.83 million, a price-to-earnings ratio of -1.29 and a beta of 1.39. Nautilus Biotechnology has a 12 month low of $0.66 and a 12 month high of $3.09. The firm’s fifty day moving average price is $1.08 and its 200 day moving average price is $1.79.

Insider Activity at Nautilus Biotechnology

In other news, CEO Sujal M. Patel acquired 53,300 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was acquired at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the transaction, the chief executive officer now owns 10,117,788 shares in the company, valued at approximately $10,016,610.12. The trade was a 0.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 40.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nautilus Biotechnology

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Nautilus Biotechnology by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company’s stock worth $1,920,000 after purchasing an additional 7,000 shares during the period. Clarius Group LLC boosted its stake in shares of Nautilus Biotechnology by 36.1% during the 1st quarter. Clarius Group LLC now owns 866,586 shares of the company’s stock worth $746,000 after acquiring an additional 230,054 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Nautilus Biotechnology by 11.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company’s stock worth $1,294,000 after acquiring an additional 78,367 shares during the period. Wexford Capital LP increased its stake in Nautilus Biotechnology by 42.4% in the 4th quarter. Wexford Capital LP now owns 325,239 shares of the company’s stock valued at $546,000 after purchasing an additional 96,889 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Nautilus Biotechnology by 61.7% during the fourth quarter. Renaissance Technologies LLC now owns 250,221 shares of the company’s stock worth $420,000 after purchasing an additional 95,521 shares during the last quarter. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.